文献速递临床试验与 GCP

安慰剂对照交叉试验:噻托溴铵或安慰剂联合常规治疗对稳定期症状性造血干细胞移植后闭塞性细支气管炎综合征的疗效

A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS).
PubMed 文献 · Trials · 2024-04-06

一项随机、双盲、安慰剂对照交叉临床试验,纳入20例造血干细胞移植后闭塞性细支气管炎综合征(BOS)患者,1:1随机接受每日一次吸入噻托溴铵18 mcg或安慰剂治疗1个月,联合常规标准治疗,评估肺功能及6分钟步行试验。研究于2022年9月开始招募,随访预计2024年4月结束,结果尚未报告。

要点

  • BOS是造血干细胞移植后移植物抗宿主病的肺部表现,发病率和死亡率高,尚无标准治疗。
  • 基于BOS与慢性阻塞性肺疾病的相似性,提出使用噻托溴铵作为支气管扩张剂。
  • 该试验为随机双盲安慰剂对照交叉设计,样本量20例,主要评估肺功能及6分钟步行试验。

核心结论

  • 该试验旨在评估噻托溴铵对造血干细胞移植后BOS患者的疗效,目前随访仍在进行中,结果尚未报告。

研究设计与样本

  • 随机、双盲、安慰剂对照交叉临床试验,共20例BOS患者按1:1随机分配。
  • 干预为每日一次吸入噻托溴铵溴化物(KP-Tiova Rotacaps 18 mcg,Cipla,印度)或安慰剂,持续1个月,联合常规标准治疗。
  • 评估指标包括肺量计检查和6分钟步行试验。
  • 研究获德黑兰医科大学伊玛目霍梅尼医院综合体研究伦理委员会批准,招募于2022年9月开始。
  • 试验注册号:伊朗临床试验注册库(IRCT)IRCT20200415047080N3,注册日期2022年7月12日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the fundamental progress in hematopoietic stem cell transplant, this treatment is also associated with complications. Graft-versus-host disease is a possible complication of HSCT. Bronchiolitis obliterans syndrome (BOS) is the pulmonary form of this syndrome. Due to the high morbidity and mortality rate of BOS, various studies have been conducted in the field of drug therapy for this syndrome, although no standard treatment has yet been proposed. According to the hypotheses about the similarities between BOS and chronic obstructive pulmonary disease, the idea of using tiotropium bromide as a bronchodilator has been proposed. METHOD/DESIGN: A randomized, double-blind, placebo-controlled, and crossover clinical trial is being conducted to evaluate the efficacy of tiotropium in patients with BOS. A total of 20 patients with BOS were randomly assigned (1:1) to receive a once-daily inhaled capsule of either tiotropium bromide (KP-Tiova Rotacaps 18 mcg, Cipla, India) or placebo for 1 month. Patients will receive tiotropium bromide or placebo Revolizer added to usual standard care. Measurements will include spirometry and a 6-min walking test. ETHICS/DISSEMINATION: This study was approved by the Research Ethics Committees of Imam Khomeini Hospital Complex, Tehran University of Medical Science. Recruitment started in September 2022, with 20 patients randomized. The treatment follow-up of participants with tiotropium is currently ongoing and is due to finish in April 2024. The authors will disseminate the findings in peer-reviewed publications, conferences, and seminar presentations. TRIAL REGISTRATION: Iranian Registry of Clinical Trial (IRCT) IRCT20200415047080N3. Registered on 2022-07-12, 1401/04/21.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dini N, Khoshbin AP, Aliannejad R, et al. A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS). Trials. 2024. PMID: 38582877. doi:10.1186/s13063-024-08051-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。